TLX
Telix·NASDAQ
--
--(--)
--
--(--)
TLX fundamentals
Telix (TLX) released its earnings on Aug 21, 2025: revenue was -- (YoY --), beat estimates; EPS was -- (YoY --), missed estimates.
Revenue / YoY
--
--
EPS / YoY
--
--
Report date
Aug 21, 2025
TLX Earnings Call Summary for Q2,2025
- Revenue Growth: 63% YoY to $390M, driven by Illuccix (30% YoY) and RLS integration.
- Strategic Investments: $82M in R&D (47% YoY) for therapeutics pipeline; $207M cash on hand for M&A.
- RLS Synergies: 50% Illuccix dose volume growth through RLS; U.S. radio metal network expansion planned.
- Clinical Innovation: BiPASS study to reduce prostate cancer biopsies; Gozellix F-18/AlF technology addresses physician preference.
- Therapeutics Catalysts: 3 Phase III trials (prostate, kidney, neuro-oncology) with PDUFA dates in 2025-26.
EPS
Actual | |
Forecast | 0.137676 |
Surprise | 0.00% |
Revenue
Actual | -- |
Forecast | 316.00M |
Surprise | 0.00% |
Earnings Call
You can ask Aime
What were the key takeaways from Telix’s earnings call?Did Telix beat or miss consensus estimates last quarter?What guidance did Telix's management provide for the next earnings period?What is Telix's gross profit margin?What is the revenue and EPS growth rate for Telix year over year?What does Telix do and what are its main business segments?What were the key takeaways from Telix's earnings call?What factors drove the changes in Telix's revenue and profit?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
